Key products by therapeutic area
-
Multiple sclerosis (MS): REBIF®
-
Oncology: ERBITUX® (solid tumors)
-
Fertility:GONAL-F®, PERGOVERIS™, LUVERIS®, OVIDREL®/OVITRELLE®, CRINONE®, CETROTIDE® (infertility treatment)
-
Endocrinology: SAIZEN® (growth disorders), SEROSTIM® (HIV-associated wasting), EGRIFTA® (HIV-associated abdominal lipohypertrophy), KUVAN® (metabolic disorder hyperphenylalaninemia)
-
CardioMetabolic Care: CONCOR® franchise (cardiovascular diseases), GLUCOPHAGE® franchise (type 2 diabetes), EUTHYROX® (thyroid disorders)
Key developments in 2011
-
Sales of ERBITUX® rise 4.3% to € 855 million, REBIF® sales increase by 1.4% to € 1,691 million
-
Extended indication of REBIF® to treat patients with early signs of multiple sclerosis approved in Europe
-
Application to extend the indication of ERBITUX® to first-line therapy of advanced or metastatic non-small cell lung cancer in patients with high EGFR expression submitted again in the EU
-
Following negative feedback from the drug regulatory authorities in the United States and the EU, Merck Serono decides not to pursue further the worldwide approval process for cladribine tablets
-
All rights for safinamide returned to Newron as part of the review and reprioritization of the R&D pipeline
-
Launch of three new pre-filled pens for the self-administration of GONAL-F®, LUVERIS® and OVIDREL® in select markets
back
